We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High Blood Sugar in Diabetes Disrupts Mitochondrial Enzyme Activity

By LabMedica International staff writers
Posted on 20 May 2015
The damage caused to the body by the high levels of blood sugar that characterize diabetes seems to be due to disturbances caused in the activity of a critical mitochondrial enzyme.

Investigators at Johns Hopkins University (Baltimore, MD, USA) worked with a rat diabetes model. More...
They were particularly interested in the metabolic pathways involved in O-linked N-acetylglucosaminylation (O-GlcNAcylation), a reversible post-translational modification in which a sugar moiety is added to serine/threonine residues of cytosolic or nuclear proteins. Catalyzed by O-GlcNAc-transferase (OGT) and removed by O-GlcNAcase (OGA), this dynamic modification is dependent on environmental glucose concentration. O-GlcNAcylation regulates the activities of a wide panel of proteins involved in almost all aspects of cell biology.

The investigators reported in the April 27, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that analyses of purified rat heart mitochondria from normal and streptozocin-treated diabetic rats showed strikingly different OGT and OGA localizations and expression levels. Live cell OGA activity assays established the presence of O-GlcNAcase within the mitochondria. Furthermore, the inner mitochondrial membrane transporter, pyrimidine nucleotide carrier, transported UDP-GlcNAc from the cytosol to the inside of the mitochondria. Knockdown of this transporter substantially lowered mitochondrial O-GlcNAcylation.

In addition, inhibition of OGT or OGA activity within neonatal rat cardiomyocytes significantly affected energy production, mitochondrial membrane potential, and mitochondrial oxygen consumption.

"Sugar itself is not toxic, so it has been a mystery why high blood sugar can have such a profound effect on the body," said senior author Dr. Gerald Hart, professor of biological chemistry at Johns Hopkins University. "The answer seems to be that high blood sugar disrupts the activity of a molecule that is involved in numerous processes within the cell. The net effect of the changes in O-GlcNAc-related activity is to make energy production in the mitochondria less efficient so that the mitochondria begin to produce more heat and damaging molecules as byproducts of the process."

Related Links:

Johns Hopkins University



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.